Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 26, 2025

Stocks Settle Higher as US Economic News Lifts Fed Rate Cut Expectations

View original at nasdaq.com
Stocks Settle Higher as US Economic News Lifts Fed Rate Cut Expectations The S&P 500 Index ($SPX) (SPY) on Tuesday closed up by +0.91%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +1.43%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +0.58%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • An agreement between Meta and Google would suggest Google is making headway in efforts to rival Nvidia's AI accelerator chips

    80% confidence
  • 2026 revenue forecast raised to $4.85 billion-$4.86 billion from previous $4.83 billion-$4.84 billion

    80% confidence
  • 2026 net sales forecast lowered to +3.5% to +4.5% from previous +3% to +5%

    80% confidence
  • Q1 revenue forecast of $1.53 billion to $1.55 billion

    80% confidence
  • 83% of reporting S&P 500 companies exceeded Q3 earnings forecasts, on course for the best quarter since 2021

    80% confidence
  • Full-year comparable sales forecast raised to -2.5% to -3.0% from previous -4% to -5%

    80% confidence
  • Q1 revenue forecast of $610 million to $630 million

    80% confidence
  • Meta Platforms is in talks to spend billions on Google's AI chips (TPUs) in data centers in 2027

    80% confidence
  • 2026 revenue forecast raised to $41.65 billion-$41.95 billion from previous $41.1 billion-$41.9 billion

    80% confidence
  • Q1 revenue forecast of $3.0 billion to $3.2 billion

    80% confidence
  • Q3 earnings rose +14.6%, more than doubling expectations of +7.2% y/y

    80% confidence
  • Oracle stock downgraded to hold from buy with price target cut to $230 from $350

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Stocks Settle Higher as US Economic News Lifts Fed Rate Cut Expectations — Source | Via News | ViaNews EU